Elimination of Sestrin 2 Compromises Viability in Extracellular Matrix-Detached SKOV3 Ovarian Cancer Cells

  • Yadira Gonzalez Department of Biology, Saint Mary’s College, Notre Dame, IN 46556, USA
  • Leann Tulisiak Department of Biology, Saint Mary’s College, Notre Dame, IN 46556, USA
  • Mary Philbin Department of Biology, Saint Mary’s College, Notre Dame, IN 46556, USA
  • Hannah Voss Department of Biology, Saint Mary’s College, Notre Dame, IN 46556, USA
  • Ethan Schramm Department of Biology, Saint Mary’s College, Notre Dame, IN 46556, USA
  • Irma Ruelas Department of Biology, Saint Mary’s College, Notre Dame, IN 46556, USA
  • Calli A. Davison-Versagli Department of Biology, Saint Mary’s College, Notre Dame, IN 46556, USA
Keywords: Extracellular matrix; Ovarian cancer; Reactive oxygen species; Sestrin

Abstract

Epithelial ovarian carcinoma (EOC) is considered the deadliest gynecological cancer, largely due to the fact that it is often diagnosed once the cancer has already metastasized, thus making the disease more difficult to treat. Throughout metastasis, ovarian epithelial cancer cells must overcome many feats, including surviving in extracellular matrix (ECM) detachment. ECM-detached cancer cells must evade a number of insults, including increased intracellular reactive oxygen species (ROS). Recent evidence suggests ECM-detached cancer cells rely on antioxidant enzymes to combat these increasing levels of ROS to promote survival; however, the specific antioxidant enzymes involved in this process have yet to be fully elucidated. Sestrin 2 (SESN2) is a multi-functional protein that has been found to be instrumental in many different signaling pathways; notably, it has been recognized to play a critical role in eliminating ROS. Here, we show that SESN2 plays a unique role in maintaining the viability of ECM-detached metastatic ovarian epithelial cancer cells, and elimination of this critical protein results in compromised viability. Thus, these data identify SESN2 as a potentially interesting therapeutic target for treating this deadly metastatic disease.

Published
2019-11-01
How to Cite
Gonzalez, Y., Tulisiak, L., Philbin, M., Voss, H., Schramm, E., Ruelas, I., & Davison-Versagli, C. A. (2019). Elimination of Sestrin 2 Compromises Viability in Extracellular Matrix-Detached SKOV3 Ovarian Cancer Cells. Reactive Oxygen Species, 8(24), 332–340. Retrieved from https://www.aimsci.com/ros/index.php/ros/article/view/247
Section
Original Research Articles